Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats
This study examined the effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats.Male albino rats (200–350 g) were fasted overnight and DM was induced by a single dose 40 mg/kg of streptozotocin (i.p.). After 48 h, DM was confirmed (blood sugar ≥200 mg/dl) and the animals were grouped into normal rats with no drug treatment, untreated diabetic animals and groups treated with glibenclamide, glibenclamide plus amlodipine, and glibenclamide plus valsartan. After six weeks treatment, animals were sacrificed under chloroform anaesthesia. Kidney, liver, lung, heart and bl...
Source: Biomedicine and Pharmacotherapy - July 12, 2018 Category: Drugs & Pharmacology Source Type: research

Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats.
This study examined the effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats. Male albino rats (200-350 g) were fasted overnight and DM was induced by a single dose 40 mg/kg of streptozotocin (i.p.). After 48 h, DM was confirmed (blood sugar ≥200 mg/dl) and the animals were grouped into normal rats with no drug treatment, untreated diabetic animals and groups treated with glibenclamide, glibenclamide plus amlodipine, and glibenclamide plus valsartan. After six weeks treatment, animals were sacrificed under chloroform anaesthesia. Kidney, liver, lung, heart and blood w...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 2, 2018 Category: Drugs & Pharmacology Authors: Bolanle IO, Omogbai EKI, Bafor EE Tags: Biomed Pharmacother Source Type: research

Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized-controlled versus observational studies.
Authors: Sison J, Vega RMR, Dayi H, Bader G, Brunel P Abstract OBJECTIVE: The aim of this post-hoc analysis was to compare the results from randomized-controlled trials (RCTs) and real-world evidence (RWE) studies of valsartan/amlodipine (Val/Aml) and valsartan/amlodipine/hydrochlorothiazide (Val/Aml/HCTZ) in patients with uncontrolled hypertension (>140/90 mmHg). METHODS: Data were pooled from 15 RCTs (N = 5542), 8 RWE studies (N = 1397) for Val/Aml; and 2 RCTs (N = 804), 5 RWE studies (N = 9380) for Val/Aml/HCTZ. Patients who received Val/Aml (...
Source: Current Medical Research and Opinion - December 8, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study.
Authors: Štulc T, Lánská V, Šnejdrlová M, Vrablík M, Prusíková M, Češka R Abstract INTRODUCTION: The aim of study was to investigate the possibility of cardiovascular risk improvement through systematic identification of high-risk individuals and treatment in accordance with current guidelines using modern therapy in daily clinical practice. MATERIAL AND METHODS: Two hundred and sixty-three physicians participated in the study. The physicians were asked to screen for cardiovascular risk factors in patients presenting with unrelated problems and to ...
Source: Archives of Medical Science - July 20, 2017 Category: General Medicine Tags: Arch Med Sci Source Type: research

Development, validation and comparison of near infrared and Raman spectroscopic methods for fast characterization of tablets with amlodipine and valsartan.
The objective of this study was to develop, validate and compare NIR and Raman spectroscopic methods for fast characterization in terms of API content and tensile strength of fixed-dose combination tablets containing amlodipine and valsartan. For the APIs assay NIR-transmittance and Raman-reflectance methods were considered, whereas for the tensile strength assay Raman spectra were recorded in reflectance configuration and NIR spectra were recorded in both reflectance and transmittance. Multivariate calibration models (PLS) were built by applying different pre-processing methods (SNV, MSC, SD+SNV) on certain spectral regio...
Source: Talanta - March 29, 2017 Category: Chemistry Authors: Casian T, Reznek A, Vonica-Gligor AL, Van Renterghem J, De Beer T, Tomuță I Tags: Talanta Source Type: research

Effects of Amlodipine and Valsartan on Blood Pressure Variability and Pulse Wave Velocity in Hypertensive Patients.
This study was a prospective, randomized, parallel, case-controlled trial performed in a medical center. A total of 134 outpatients newly diagnosed with essential hypertension or receiving low-dose monotherapy were enrolled and 119 completed the trial. They were randomized into amlodipine 10mg group (n = 40), valsartan 160mg group (n = 38) and amlodipine 5mg + valsartan 80mg (n = 41) in a 1:1:1 allocation ratio for a 10-week treatment. Demographic data and laboratory indicators were collected at the randomization and 10 weeks after the treatment. The 24-hour ambulatory BP and brachial-ankle PWV were also monitored. RE...
Source: The American Journal of the Medical Sciences - January 1, 2017 Category: Journals (General) Authors: Shi R, Liu K, Shi D, Liu Q, Chen X Tags: Am J Med Sci Source Type: research

Quantitative model for the blood pressure ‐lowering interaction of valsartan and amlodipine
ConclusionPKPD models for SBP and DBP successfully described the time course of the antihypertensive effects of amlodipine and valsartan. An infra‐additive interaction between amlodipine and valsartan when used in combined administration was confirmed and quantified. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - October 3, 2016 Category: Drugs & Pharmacology Authors: Young ‐A Heo, Nick Holford, Yukyung Kim, Mijeong Son, Kyungsoo Park Tags: PHARMACOKINETIC DYNAMIC RELATIONSHIPS Source Type: research

Quantitative Model for the Blood Pressure Lowering Interaction of Valsartan and Amlodipine
ConclusionPKPD models for SBP and DBP successfully described the time course of the antihypertensive effects of amlodipine and valsartan. An infra‐additive interaction between amlodipine and valsartan when used in combined administration was confirmed and quantified. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - August 10, 2016 Category: Drugs & Pharmacology Authors: Young ‐A Heo, Nick Holford, Yukyung Kim, Mijeong Son, Kyungsoo Park Tags: PHARMACOKINETIC DYNAMIC RELATIONSHIPS Source Type: research

Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan.
Authors: Celık T, Balta S, Karaman M, Ahmet Ay S, Demırkol S, Ozturk C, Dınc M, Unal HU, Yılmaz MI, Kılıc S, Kurt G, Tas A, Iyısoy A, Quartı-Trevano F, Fıcı F, Grassı G Abstract Vascular inflammation plays an important role in the pathophysiology of hypertension and high levels of endocan may reflect ongoing vascular inflammation in hypertensive patients. In the present hypothesis-generating study, we aimed at investigating the comparative effects of amlodipine and valsartan on endocan levels in newly diagnosed hypertensive patients. The study population consisted of 37 untreated hypertensive patients wh...
Source: Blood Pressure - February 14, 2016 Category: Hematology Tags: Blood Press Source Type: research

Antihypertensive nano-ceuticales based on chitosan biopolymer: Physico-chemical evaluation and release kinetics
Publication date: 20 May 2016 Source:Carbohydrate Polymers, Volume 142 Author(s): Taskeen Niaz, Saima Shabbir, Shahid Manzoor, Asma Rehman, Abdur Rahman, Habib Nasir, Muhammad Imran Prime risk factor behind cardiovascular associated mortality and morbidity is hypertension. The main challenge with antihypertensive (AHT) drug therapy is their extreme hydrophobic nature and very low oral bio-availability; which result into higher dosage/frequency and associated side effects of drugs. The main objective of this study was to fabricate AHT nano-ceuticals in hydrophilic carriers of natural origin to improve drugs′ ...
Source: Carbohydrate Polymers - February 7, 2016 Category: Biomedical Science Source Type: research

Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
Authors: Setiawati A, Kalim H, Abdillah A Abstract AIM: to assess the effectiveness, safety and tolerability of amlodipine/valsartan (Aml/Val) single-pill combination (SPC) in hypertensive patients in a real-world setting. METHODS: the Indonesian subset of the EXCITE (clinical EXperience of amlodIpine and valsarTan in hypErtension) study, which was a multinational, prospective, observational, open study in hypertensive patients treated with Aml/Val SPC for 26 weeks. Aml/Val SPCs (5/80, 5/160, 10/160 mg) were administered as monotherapy or as add-on therapy to other antihypertensive medications in patients not c...
Source: Acta medica Indonesiana - December 11, 2015 Category: Internal Medicine Tags: Acta Med Indones Source Type: research

Improvement in Hemodynamics After Methylene Blue Administration in Drug-Induced Vasodilatory Shock: A Case Report.
DISCUSSION: Methylene blue may improve hemodynamics in drug-induced vasodilatory shock and should be considered in critically ill patients poisoned with vasodilatory medications refractory to standard therapies. PMID: 26310944 [PubMed - as supplied by publisher] (Source: Journal of Medical Toxicology)
Source: Journal of Medical Toxicology - August 27, 2015 Category: Toxicology Authors: Laes JR, Williams DM, Cole JB Tags: J Med Toxicol Source Type: research

New methods for amlodipine and valsartan native spectrofluorimetric determination, with factors optimization study.
Abstract Four native fluorescence methods were suggested for simultaneous determination of amlodipine (AML) and valsartan (VAL). These methods were based on excitation of both drugs at λex 300nm, in one step, to give maximum emission at λem 378 and 496nm for AML and VAL, respectively. The first method, single λex method, was used without any additions. The sensitivity of this method was further increased by the addition of hydroxy propylmethyl cellulose (HPMC) surfactant, β-cyclodextrin, or ferric oxide magnetite nanoparticles, in the other three methods. Different types of surfactants, a...
Source: Talanta - June 19, 2015 Category: Chemistry Authors: El-Kosasy AM, Tawakkol SM, Ayad MF, Sheta AI Tags: Talanta Source Type: research

Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study
Objective: Beneficial effects of continuous positive airway pressure (CPAP) on both blood pressure (BP) levels and variability have been documented in patients with obstructive sleep apnoea (OSA). We investigated the relevant impact of different dosing times of antihypertensive drugs beyond CPAP application. Methods: In this prospective, cross-over trial, we included 41 patients with newly diagnosed hypertension and never treated OSA (apnoea-hypopnea index ≥15/h), without increased daytime somnolence (Epworth Score ≤10 points). Patients first received treatment with valsartan or with a fixed combination of amlodipine...
Source: Journal of Hypertension - January 6, 2015 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research

Electroanalytical application of a boron-doped diamond electrode: improving the simultaneous voltammetric determination of amlodipine and valsartan in urine and combined dosage forms
Publication date: Available online 27 November 2014 Source:Journal of Electroanalytical Chemistry Author(s): Guilherme Roberto Mansano , Ana Paula Pires Eisele , Luiz Henrique Dall’Antonia , Sabrina Afonso , Elen Romão Sartori A new voltammetric method was developed for simultaneous determination of amlodipine (AML) and valsartan (VAL) in synthetic urine and combined pharmaceutical formulations. The anodic peak potentials of AML and VAL oxidation at a cathodically pretreated boron-doped diamond electrode were found to be 0.791 V and 1.37 V (vs. Ag/AgCl (3.0 mol L−1 KCl)), respectively, by cyclic voltam...
Source: Journal of Electroanalytical Chemistry - November 30, 2014 Category: Chemistry Source Type: research

Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan
Blood Pressure, Ahead of Print. (Source: Blood Pressure)
Source: Blood Pressure - November 13, 2014 Category: Hematology Tags: article Source Type: research

Health Care Utilization and Cost Comparison Between Adherent Hypertension Patients Treated by Single Exforge HCT and Amlodipine/Valsartan/Hydrochlorothiazide Free Combination
This study investigated if Exforge HCT is associated with reduced health care utilization and costs during the 12 months follow up period in adult hypertensive (HTN) patients adherent to treatment. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: W Chen, Z Wei, SH Ong, G Machnicki, K Kristijan Source Type: research

Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin–Angiotensin–Aldosterone System Antagonists
Health care providers managing hypertension (HTN) have a large selection of pharmacologic agents to choose from, including several different classes of drugs and many similar drugs within each class. Antagonism of the renin–angiotensin–aldosterone system has been shown to be very effective for HTN, especially in patients with cardiovascular disease, diabetes, and heart failure. Within this group, there have been 2 new agents recently introduced to the US market and approved by the Food and Drug Administration. It is important for the HTN specialist to be familiar with the merits of these 2 drugs: the angiotensi...
Source: American Journal of Therapeutics - September 1, 2014 Category: Drugs & Pharmacology Tags: Therapeutic Review Source Type: research

Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan
Objective: EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) evaluated the real-life effectiveness, safety, and tolerability of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from 13 countries in the Middle East and Asia. Here, we present data from Pakistan. Methods: This was a 26-week observational, multicenter, prospective, open-label study. At week 26, change from baseline in mean sitting systolic (msSBP) and diastolic blood pressure (msDBP) and the proportion of patients achieving BP goal (SBP/DBP
Source: Therapeutic Advances in Cardiovascular Disease - March 18, 2014 Category: Cardiology Authors: Khan, W., Moin, N., Iktidar, S., Sakrani, J., Abid, R., Afzal, J., Maheshwary, N., Kumar, K., Siddiqi, A., Qadir, M. Tags: Original Research Source Type: research

Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function
Conclusions: In our sample of individuals with hypertension and diastolic dysfunction, older compared to younger adults experienced less improvement in diastolic function in response to similar reductions in SBP. (Source: Journal of Hypertension)
Source: Journal of Hypertension - December 17, 2013 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research

The Comparative Effects of Valsartan and Amlodipine on vWf Levels and N/L Ratio in Patients with Newly Diagnosed Hypertension.
Abstract High levels of circulating Von Willebrand factor (vWf) and increased neutrophil to lymphocyte (N/L) ratio may reflect vascular inflammation in hypertensive patients. In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calcium channel blocker on the vWf levels and N/L ratio in patients with essential hypertension. Patients were randomized to one of the following intervention protocols: calcium channel blocker (amlodipine, 5-10 mg/day) as group A (n = 20 mean age = 51.85 ± 11.32 y) and angio...
Source: Clinical and Experimental Hypertension - January 4, 2013 Category: Cardiology Authors: Karaman M, Balta S, Ay SA, Cakar M, Naharci I, Demirkol S, Celik T, Arslan Z, Kurt O, Kocak N, Sarlak H, Demirbas S, Bulucu F, Bozoglu E Tags: Clin Exp Hypertens Source Type: research